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FOREWORD: 
DRUG-DRUG INTERACTION WARNINGS AS TECHNOLOGICAL 
IATROGENESIS* 
NICOLAS P. TERRY** 
The Health Information Technology for Economic and Clinical Health 
Act (“HITECH”) contained within the American Recovery and Reinvestment 
Act of 2009 (“ARRA”) provided approximately $30 billion for Health and 
Human Services’ Agencies: approximately $27 billion for the Centers for 
Medicare and Medicaid Services (“CMS”) and $2 billion for the Office of 
the National Coordinator (“ONC”).  The $27 billion was to fund Medicaid 
and Medicare incentive payments to non-hospital-based doctors (“eligible 
providers”) and eligible hospitals conditioned on their “meaningful use of 
certified EMR technology.”1  The incentive payments to providers to adopt 
electronic medical records (“EMR”) are one component in a broader 
strategy to promote the adoption of health information technology (“HIT”) in 
the United States.  In large part this is because research suggests that the 
benefits of EMR adoption are increased significantly when accompanied by 
other technologies such as computerized order entry (“CPOE”) and clinical 
decision support (“CDS”) modules.2 
EMR, CPOE and CDS have great potential to reduce the incidence of 
avoidable adverse events (including medication errors).3 Yet, these 
 
* Copyright © 2012, Nicolas P. Terry. All Rights Reserved. 
** Hall Render Professor of Law & Co-Director Hall Center for Law and Health, Indiana 
University Robert H. McKinney School of Law. Email: npterry@iupui.edu. 
 1. See generally Nicolas P. Terry, Certification and Meaningful Use of Electronic Health 
Records: Reframing Adoption as a Quality and Reimbursement Imperative, 8 IND. HEALTH L. 
REV. 45 (2011); Nicolas P. Terry, Anticipating Stage Two: Assessing the Development of 
Meaningful Use and EMR Deployment, 21 ANNALS HEALTH L. 103. 
 2. See generally David W. Bates et al., Effect of Computerized Physician Order Entry and 
a Team Intervention on Prevention of Serious Medication Errors, 280 JAMA 1311 (1998); 
Catherine M. DesRoches et al., Electronic Health Records’ Limited Successes Suggest More 
Targeted Uses, 29 HEALTH AFF. 639 (2010). 
 3. Cf. Daria O’Reilly et al., Cost-Effectiveness of a Shared Computerized Decision 
Support System for Diabetes Linked to Electronic Medical Records, J. AM. MED. INFORMATICS 
ASS’N (Nov. 3, 2011), http://jamia.bmj.com/content/early/2011/11/03/amiajnl-2011-
000371.full.pdf (showing only marginal improvement in trial involving treatment of diabetes 
type 2). 
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technologies themselves possess error profiles and so the potential to add to 
iatrogenic injuries.4  As noted by Harrington and colleagues: 
While hospital electronic medical records (EMR) are intended to reduce 
medical errors, several aspects of the EMR may actually increase the 
incidence of certain types of errors or produce new safety risks that result in 
harm.  Threats to patient safety can be introduced during any phase of the 
EMR lifecycle, such as planning, design, development, testing, 
implementation, operations, and maintenance.  Within each of these 
processes, technology, people, and the work environment can individually 
or collectively generate errors.5 
In a timely study that likely will exert considerable influence on the 
design of future HIT safety models M. Susan Ridgely and Michael 
Greenberg critically examine Drug-Drug Interaction (“DDI”) alerts initiated 
by CDS systems.  Specifically, they explore two related phenomena; first, the 
tendency of CDS to generate a very large number of DDI alerts that leads to 
high sorting costs for physicians (they appropriately term this “alert fatigue”) 
and, second, the liability disincentives that create barriers to some possible 
solutions to this alert fatigue.  Such solutions could include more physician 
choice in electing to receive fewer or filtered alerts (arguably increasing 
physician exposure to malpractice liability) or a reduced DDI model in the 
CDS (arguably increasing manufacturer exposure to products liability).  As 
the authors note, “What is needed is an optimized DDI list, but vendors are 
unlikely to produce one, given their concern that excluding any potential 
drug interactions from the list (or allowing their clients to do so) exposes the 
vendor to additional liability risk.”6  There is the additional danger that CDS 
manufacturers will tend towards the production of “defensive” software 
featuring over-inclusive DDI lists. 
In the absence of any discovered “legal ‘magic bullet’” the authors 
analyze the amelioratory potential of five strategies to address liability 
concerns.7  First, a national “expert” process that would then create a norm 
in medical malpractice claims (although it would be of less utility in products 
 
 4. Patrick A. Palmieri et al., Technological Iatrogenesis: New Risks Force Heightened 
Management Awareness, J. HEALTHCARE RISK MGMT., Autumn (Fall) 2007, at 19. 
 5. Linda Harrington et al., Safety Issues Related to the Electronic Medical Record (EMR): 
Synthesis of the Literature from the Last Decade, 2000-2009, 56 J. HEALTHCARE MGMT. 31 
(2011); see generally Nicolas P. Terry, When the “Machine That Goes ‘Ping’” Causes Harm: 
Default Torts Rules and Technologically-Mediated Health Care Injuries, 46 St. Louis U. L.J. 37 
(2002). 
 6. M. Susan Ridgely & Michael D. Greenberg, Too Many Alerts, Too Much Liability: 
Sorting Through the Malpractice Implications of Drug-Drug Interaction Clinical Decision 
Support, 5 ST. LOUIS U. J. HEALTH L. & POL’Y 257, 259 (2012). 
 7. Id. at 263. 
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liability cases where custom-based evidence is viewed less favorably).8  
Second, FDA regulation coupled with preemption.9  Third, incorporating an 
optimized DDI list in meaningful use (presumably stage 3).10  Fourth, 
including an optimized DDI list in ONC’s meaningful use certification 
requirements.11  Fifth, introducing federal legislation that contains a safe 
harbor for those who adopt an approved DDI list.12 
Ridgely and Greenberg identify an intrinsically important issue: the 
practical and legal implications of a non-optimized DDI list.  But, that issue 
serves also as a broader metaphor.  Anyone who has seen a physician 
wrestle with a newly introduced EMR terminal in his or her office will 
appreciate the flaws in the early generations of HIT appliances.  Over-
inclusive data presentation models, relatively unsophisticated interface 
design, and steep learning curves experienced by health care professionals 
are colliding with accelerating adoption curves promoted by HHS and 
embraced by healthcare entities eager to share in the meaningful use 
bounty. 
The importance of the issue can further be gauged from the quality of 
the commentaries that follow.  Sharona Hoffman and Andy Podgurski,13 two 
of the leading academic commentators on the safety of HIT products, 
address the operational pieces missing from Ridgely and Greenberg’s 
article—exactly what is meant by a clinically significant DDI list and what 
would be the process to achieve such a list.  Their conclusion is that context 
or patient specific parsing of DDI information (informed by expert-designed 
algorithms and patient-specific EHR data) is preferable to notional or 
canonical lists. 
In his commentary Dr. Ross Koppel14 points out that CDS issues go 
beyond the DDI problems identified by Ridgely and Greenberg, extending to 
many more data sets, that the amount of data and the lack of clear 
evidence-based discriminators between CDS alerts make for a frustrating 
user experience, and a lack of consistency among products and 
implementing facilities.  His plea is for better CDS systems as well as 
improved liability options. 
 
 8. Id. at 279. 
 9. Id. at 281. 
 10. Id. at 286. 
 11. Ridgely & Greenberg, supra note 6, at 289. 
 12. Id. at 290. 
 13. Sharona Hoffman & Andy Podgurski, Drug-Drug Interaction Alerts: Emphasizing the 
Evidence, 5 ST. LOUIS U. J. HEALTH L. & POL’Y 297 (2012). 
 14. Ross Koppel, The Marginal Utility of Marginal Guidance: Commentary on Too Many 
Alerts, Too Much Liability: Sorting Through the Malpractice Implications of Drug-Drug 
Interaction Clinical Decision Support by M. Susan Ridgely and Michael D. Greenberg, 5 ST. 
LOUIS U. J. HEALTH L. & POL’Y 311 (2012). 
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Dr. David Bates15 stresses the major safety benefits of CDS systems, 
detailing their positive worth even compared to EMR.  He expresses his core 
agreement with Ridgely and Greenberg as “clinical decision support is 
especially tricky, since not having enough is a problem, but so is having too 
many false positive warnings.”16  While generally approving of Ridgely and 
Greenberg’s five strategies, Bates emphasizes that “the vast bulk of DDIs 
including most of the ones with clinical consequences occur in the range 
that is in the middle of these two [clinically significant and insignificant] 
areas.”17 
Finally, Jodi Daniel18 from ONC provides the important policymaker’s 
perspective and, specifically, the appropriateness of regulation.  In Daniel’s 
view “in the case of DDI alerts and liability, the market has not developed a 
solution for the liability risk. This failure impedes quality and safety 
improvements in health care.”19 However, she is cool to all out FDA 
regulation preferring a more targeted approach to improving CDS interfaces 
to reduce alert fatigue. 
Ridgely and Greenberg, together with their commentators identify an 
important issue and lay much of the groundwork for what is likely to be a 
fascinating policy tussle.  As is well known, the FDA has been monitoring 
iatrogenic HIT events and has characterized its own regulatory inaction as 
an exercise of discretion as it evaluates the field.20  Notwithstanding, there is 
some evidence that the FDA has developed a roadmap for HIT regulation.21  
To assuage ONC and CMS concerns that FDA regulation would slow the 
meaningful use rollout the Institute of Medicine (“IOM”) was asked to weigh 
in on the issue. In its November 2011 report, Health IT and Patient Safety: 
Building Safer Systems for Better Care, the IOM appears to have sided with 
ONC and CMS.  It recommends that a new entity, the Health IT Safety 
Council, should be established within HHS to collect and provide 
 
 15. David W. Bates, Clinical Decision Support and the Law: The Big Picture, 5 ST. LOUIS U. 
J. HEALTH L. & POL’Y 319 (2012). 
 16. Id. at 320. 
 17. Id. at 322. 
 18. Jodi G. Daniel, Addressing Liability and Clinical Decision Support: A Federal 
Government Role, 5 ST. LOUIS U. J. HEALTH L. & POL’Y 325 (2012). 
 19. Id. at 328. 
 20. Health Information Technology (HIT) Policy Committee Adoption/Certification 
Workgroup (testimony by Jeffrey Shuren, Dir. of FDA Ctr. for Devices and Radiological Health) 
(Feb. 25, 2010), available at http://healthit.hhs.gov/portal/server.pt/gateway/PTARGS_0_ 
10741_910717_0_0_18/3Shuren_Testimony022510.pdf. 
 21. See Medical Devices; Medical Device Data Systems, 76 Fed. Reg. 8637 (Feb. 15, 
2011); U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY AND FOOD AND DRUG 
ADMINISTRATION STAFF: MOBILE MEDICAL APPLICATIONS (2011), available at http://www.fda.gov/ 
downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM2633
66.pdf. 
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information and set safety standards.22  Reacting to the report ONC 
Coordinator Dr. Farzad Mostashari noted, “HHS agrees with IOM that more 
can and should be done to capture safety issues unique to EHRs when and if 
they arise. ONC will lead an HHS planning initiative to develop a 
comprehensive EHR safety action and surveillance plan well within the 12-
month period recommended by IOM.”23  That statement fails to mention 
that the proposed Safety Council suggests a preference for post-marketing 
surveillance absorption into meaningful use certification.  Meanwhile, and 
reinforcing Ridgely and Greenberg’s investigation of several liability-limiting 
options, Rep. Tom Marino has introduced legislation that would have the 
effect of denying FDA regulation of EMR while at the same time providing 
that reports of EHR-related adverse events will not be admissible in any 
litigation.24 
There will be many more issues related to HIT outputs that will have 
liability dimensions as the healthcare industry undergoes this overdue 
revolution.  These are all excellent contributions to the literature and on 
behalf of the editors of the Saint Louis University Journal of Health Law & 
Policy, I express our thanks to the participating authors. 
  
 
 22. COMM. ON PATIENT SAFETY & HEALTH INFO. TECH., INST. OF MED., HEALTH IT AND 
PATIENT SAFETY: BUILDING SAFER SYSTEMS FOR BETTER CARE (2011), available at 
http://www.nap.edu/openbook.php?record_id=13269&page=13. 
 23. Farzad Mostashari, Improving Patient Safety through Health IT, HEALTHITBUZZ (Nov. 8, 
2011, 5:53 PM), http://www.healthit.gov/buzz-blog/electronic-health-and-medical-records/ 
patient-safety-healthit/. 
 24. Safeguarding Access For Every Medicare Patient Act, H.R. 3239, 112th Cong. 
(2011). 
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